Preliminary injunction significantly mitigates 1260H list risk, but target-price upside is already limited

Overview

WuXi AppTec filed a lawsuit against the U.S. Department of Defense on June 11, 2026, seeking to revoke its 1260H list designation, and applied for a preliminary injunction on June 29. After reviewing the case on July 22, the U.S. District Court for the District of Columbia granted the application on August 7. Morgan Stanley believes the ruling significantly alleviates policy pressure affecting the company’s valuation and reduces the likelihood of its inclusion on the Biosecure Act’s companies of concern list.

Core views

The court’s opinion indicates that the ownership and affiliation evidence underlying the 1260H designation may have obvious deficiencies: the relevant fund’s investment in WuXi AppTec was about US$200,000, representing only about 0.001% of the company’s equity; the alleged links with defense industry regulators and the Chinese People’s Liberation Army mainly stemmed from the company processing samples as a third-party laboratory supplier, which is insufficient to prove a substantive association. Since inclusion on the 1260H list is a necessary but not sufficient condition for inclusion on the Biosecure Act’s companies of concern list, the preliminary injunction clearly reduces subsequent listing risk. Medium- to long-term fundamental drivers include multinational pharmaceutical companies increasing the outsourcing ratio for blockbuster drugs, artificial intelligence accelerating the generation of new targets and lead compounds and driving demand for wet-lab services, and margin expansion from higher capacity utilization.

Analysis framework

The report first reviews the timeline of the lawsuit and preliminary injunction, then summarizes the court’s judgments in its 35-page opinion regarding evidence of ownership, government affiliations, and military affiliations. It then analyzes the transmission relationship between the 1260H list and the Biosecure Act’s companies of concern list, and finally assesses the stock impact by combining the company’s fundamental drivers and discounted cash flow valuation.

Methodology notes

• Event-driven analysisRegulatory and litigation event transmission analysis

  Assess changes in the policy risk premium by evaluating the impact of judicial rulings on regulatory designations and subsequent legislative lists.

  The report treats the preliminary injunction as a mitigating factor for the immediate adverse consequences of the 1260H list, and judges the decline in subsequent listing probability based on the conditional relationship between the 1260H list and the Biosecure Act’s companies of concern list.

• Valuation analysisDiscounted cash flow method

  Estimate enterprise value by discounting future free cash flows and adding a terminal value.

  The A-share base case uses a 10% weighted average cost of capital and a 4% perpetual growth rate; the H-share target price is derived from the A-share target price, assuming an HKD/RMB exchange rate of 1.10.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi AppTec Co Ltd (2359.HK)

  The H-share directly covered by the report

  Strengths

  The preliminary injunction significantly alleviates policy pressure; rising outsourcing ratios among multinational pharmaceutical companies, AI-driven wet-lab demand, and higher capacity utilization support medium- to long-term growth.

  Weaknesses

  The current share price is close to the target price and 52-week high, with near-term upside of only about 0.36% based on the report’s target price.

  Comparison

  Morgan Stanley expects its risk-adjusted total return over the next 12 to 18 months to be above the average level of its China healthcare industry coverage universe.

  Risks

  The preliminary injunction is not a final judgment, and the company still faces risks from China-U.S. relations, Biosecure Act listing, customer demand, and financing cycle volatility.

• WuXi AppTec Co Ltd (603259.SS)

  The A-share valuation anchor for the H-share target price

  Strengths

  Using a company-wide discounted cash flow valuation can reflect long-term cash flow and margin improvement potential.

  Weaknesses

  The valuation is sensitive to assumptions on the weighted average cost of capital, perpetual growth rate, and long-term cash flows.

  Comparison

  The H-share target price is derived from the A-share target price combined with the HKD/RMB exchange rate assumption of 1.10.

  Risks

  Exchange-rate fluctuations and valuation differences between the A-share and H-share markets may cause the derived price to deviate from actual trading levels.

Key data

• Preliminary injunction approval date2026-08-07Temporarily mitigates the immediate adverse consequences of the 1260H designation.
• Stock ratingOverweightExpected risk-adjusted total return over the next 12 to 18 months is above the average level of the industry coverage universe.
• Industry viewAttractiveChina healthcare industry performance is expected to outperform relevant broad-market benchmarks over the next 12 to 18 months.
• H-share target priceHK$193.00Derived from the A-share target price and the HKD/RMB exchange rate assumption of 1.10.
• H-share current priceHK$192.30Closing price on August 7, 2026, implying target-price upside of about 0.36%.
• 52-week price rangeHK$96.70 to HK$193.00The current share price is already close to the upper end of the range.
• Current market capitalizationRmb451,515.0mnAs disclosed in the report.
• Current enterprise valueRmb406,128.5mnAs disclosed in the report.
• Questioned investment amountApproximately US$200kRepresents about 0.001% of WuXi AppTec’s equity, rather than the alleged 5.32% stake.
• Valuation assumptionsWeighted average cost of capital 10%, perpetual growth rate 4%Key parameters for the A-share base-case discounted cash flow valuation.

Impact & implications

The preliminary injunction reduces the near-term regulatory and customer risks WuXi AppTec faces due to the 1260H designation, and is expected to compress the policy risk premium and improve investor confidence. If the company ultimately succeeds in revoking the relevant designation, market attention may further shift to orders, revenue growth, and margin improvement. However, the current H-share price is already close to the target price and 52-week high, implying that the positive event may have been fairly well reflected, and subsequent returns will depend more on fundamental delivery and the final legal outcome.

Risks

• The preliminary injunction is not a final judgment, and the 1260H list dispute may still involve appeals, redesignation, or other procedural changes.
• The Biosecure Act’s companies of concern list will be updated in December; although the probability of inclusion has declined, it has not fallen to zero.
• China-U.S. relations and U.S. policy changes targeting Chinese biotechnology companies may push the risk premium higher again.
• End-product sales related to major commercial contracts may fall short of expectations, including the impact from the expiration of patent exclusivity periods.
• Volatility in VC/PE financing in the biotechnology industry may weaken early-stage R&D customer demand.
• The current share price is already close to the target price and 52-week high, making the valuation sensitive to the realization of positive catalysts and any fundamental shortfall versus expectations.
• Morgan Stanley discloses that it holds interests related to WuXi AppTec and has investment banking and other business relationships, so investors should pay attention to potential conflicts of interest.

What to watch

• The final ruling in the 1260H list lawsuit, appeal progress, and subsequent actions by the U.S. Department of Defense.
• The December update results for the Biosecure Act’s companies of concern list.
• Overseas customer retention, new order wins, and project transfer developments.
• The sustained intensity of multinational pharmaceutical companies’ investment in R&D and manufacturing outsourcing.
• Whether AI-driven growth in the number of new targets and lead compounds can translate into demand for wet-lab services.
• Progress in improving capacity utilization, margins, and free cash flow.
• The impact of changes in the HKD/RMB exchange rate on the derivation of the H-share target price.